
|Articles|April 1, 2003
Should a prostaglandin agent be used as initial monotherapy?
Not long after topical timolol was introduced in 1978, it became one of the most widely prescribed glaucoma medications in the world. Although timolol is considered to be the most significant therapeutic advance in the medical treatment of glaucoma in the 20th century, the 1994 introduction of prostaglandin analogs for glaucoma treatment in Japan marked the end of timolol's domination.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
2
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
3
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
4
AAO 2025: The evolution of eye care on display at AAO 2025
5